Denali Therapeutics [DNLI] vs Madrigal [MDGL] Detailed Stock Comparison
Denali Therapeutics
NASDAQ
Loading...
Madrigal
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Denali Therapeutics wins in 7 metrics, Madrigal wins in 8 metrics, with 0 ties. Madrigal appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Denali Therapeutics | Madrigal | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -6.00 | -20.23 | Madrigal |
| Price-to-Book Ratio | 2.19 | 14.14 | Denali Therapeutics |
| Debt-to-Equity Ratio | 4.67 | 17.81 | Denali Therapeutics |
| PEG Ratio | -0.27 | 0.28 | Denali Therapeutics |
| EV/EBITDA | -2.65 | -29.84 | Madrigal |
| Profit Margin (TTM) | 0.00% | -54.68% | Denali Therapeutics |
| Operating Margin (TTM) | 0.00% | -22.18% | Denali Therapeutics |
| Return on Equity | -39.69% | -36.30% | Madrigal |
| Return on Assets (TTM) | -24.99% | -18.31% | Madrigal |
| Free Cash Flow (TTM) | $-363.61M | $-462.03M | Denali Therapeutics |
| 1-Year Return | -46.79% | 103.73% | Madrigal |
| Price-to-Sales Ratio (TTM) | N/A | 19.15 | N/A |
| Enterprise Value | $1.40B | $9.20B | Madrigal |
| EV/Revenue Ratio | N/A | 17.85 | N/A |
| Gross Profit Margin (TTM) | N/A | 95.74% | N/A |
| Revenue per Share (TTM) | $0 | $23 | Madrigal |
| Earnings per Share (Diluted) | $-2.81 | $-12.63 | Denali Therapeutics |
| Beta (Stock Volatility) | 1.29 | -1.03 | Madrigal |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Denali Therapeutics vs Madrigal Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Denali Therapeutics | -2.10% | 2.62% | -3.87% | 4.56% | 28.45% | -28.50% |
| Madrigal | -1.36% | -4.88% | -3.86% | 50.87% | 40.50% | 39.04% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Denali Therapeutics | -46.79% | -54.25% | -66.25% | -30.54% | -30.54% | -30.54% |
| Madrigal | 103.73% | 574.42% | 248.38% | 529.55% | 224.61% | 26.55% |
News Based Sentiment: Denali Therapeutics vs Madrigal
Denali Therapeutics
News based Sentiment: MIXED
October was a month of contrasts for Denali, with positive analyst ratings and improved financials offset by insider selling and stock volatility. The mixed signals suggest a potentially volatile but ultimately promising investment, making it a significant month for investors to assess the company's direction.
Madrigal
News based Sentiment: POSITIVE
Madrigal Pharmaceuticals reported exceptional revenue growth in Q2 2025 and received numerous positive analyst updates, indicating strong market confidence. While some insider and institutional selling occurred, the overall narrative for the month is positive, driven by the company's financial performance and future growth prospects.
Performance & Financial Health Analysis: Denali Therapeutics vs Madrigal
| Metric | DNLI | MDGL |
|---|---|---|
| Market Information | ||
| Market Cap | $2.25B | $9.87B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 2,097,320 | 284,740 |
| 90 Day Avg. Volume | 2,250,413 | 331,680 |
| Last Close | $14.90 | $436.28 |
| 52 Week Range | $10.57 - $33.33 | $200.63 - $463.63 |
| % from 52W High | -55.30% | -5.90% |
| All-Time High | $93.94 (Dec 21, 2020) | $463.62 (Oct 01, 2025) |
| % from All-Time High | -84.14% | -5.90% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 13.54% |
| Quarterly Earnings Growth | N/A | 13.54% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | -0.55% |
| Operating Margin (TTM) | 0.00% | -0.22% |
| Return on Equity (TTM) | -0.40% | -0.36% |
| Debt to Equity (MRQ) | 4.67 | 17.81 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $7.05 | $31.32 |
| Cash per Share (MRQ) | $6.15 | $35.76 |
| Operating Cash Flow (TTM) | $-349,620,000 | $-307,412,992 |
| Levered Free Cash Flow (TTM) | $-237,644,496 | $-219,782,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Denali Therapeutics vs Madrigal
| Metric | DNLI | MDGL |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -6.00 | -20.23 |
| Forward P/E | -5.61 | -31.73 |
| PEG Ratio | -0.27 | 0.28 |
| Price to Sales (TTM) | N/A | 19.15 |
| Price to Book (MRQ) | 2.19 | 14.14 |
| Market Capitalization | ||
| Market Capitalization | $2.25B | $9.87B |
| Enterprise Value | $1.40B | $9.20B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 17.85 |
| Enterprise to EBITDA | -2.65 | -29.84 |
| Risk & Other Metrics | ||
| Beta | 1.29 | -1.03 |
| Book Value per Share (MRQ) | $7.05 | $31.32 |
Financial Statements Comparison: Denali Therapeutics vs Madrigal
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | DNLI | MDGL |
|---|---|---|
| Revenue/Sales | $0 | $137.25M |
| Cost of Goods Sold | N/A | $4.51M |
| Gross Profit | N/A | $132.74M |
| Research & Development | $116.23M | $44.17M |
| Operating Income (EBIT) | $-145.58M | $-79.31M |
| EBITDA | $-142.37M | $-69.56M |
| Pre-Tax Income | $-132.97M | $-73.24M |
| Income Tax | N/A | N/A |
| Net Income (Profit) | $-132.97M | $-73.24M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | DNLI | MDGL |
|---|---|---|
| Cash & Equivalents | $56.95M | $183.65M |
| Total Current Assets | $878.64M | $987.98M |
| Total Current Liabilities | $91.88M | $167.24M |
| Long-Term Debt | $40.05M | $118.76M |
| Total Shareholders Equity | $1.12B | $710.64M |
| Retained Earnings | $-1.67B | $-1.88B |
| Property, Plant & Equipment | $129.93M | $4.01M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | DNLI | MDGL |
|---|---|---|
| Operating Cash Flow | $-92.50M | $-81.76M |
| Capital Expenditures | $-5.08M | $0 |
| Free Cash Flow | $-136.55M | $-88.89M |
| Debt Repayment | $-4.36M | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | DNLI | MDGL |
|---|---|---|
| Shares Short | 13.08M | 4.14M |
| Short Ratio | 6.65 | 10.95 |
| Short % of Float | 0.10% | 0.22% |
| Average Daily Volume (10 Day) | 2,097,320 | 284,740 |
| Average Daily Volume (90 Day) | 2,250,413 | 331,680 |
| Shares Outstanding | 144.22M | 22.00M |
| Float Shares | 132.07M | 10.98M |
| % Held by Insiders | 0.10% | 0.08% |
| % Held by Institutions | 0.99% | 1.08% |
Dividend Analysis & Yield Comparison: Denali Therapeutics vs Madrigal
| Metric | DNLI | MDGL |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |